Impact of a novel screening program to detect acute and prevalent HIV infection and reduce HIV transmission
新型筛查计划对检测急性和流行的艾滋病毒感染并减少艾滋病毒传播的影响
基本信息
- 批准号:9336791
- 负责人:
- 金额:$ 57.26万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2016
- 资助国家:美国
- 起止时间:2016-08-24 至 2020-07-31
- 项目状态:已结题
- 来源:
- 关键词:AIDS preventionAcuteAddressAdultAfrica South of the SaharaAfricanAlgorithmsAnti-Retroviral AgentsAntigensCaringCessation of lifeClinicalConsensusCost Effectiveness AnalysisCounselingCountryCoupledDataDetectionDevelopmentDiagnosisDiagnostic testsDisease OutbreaksEarly DiagnosisEpidemicEvaluationFeverFoundationsHIVHIV InfectionsHIV diagnosisHIV-1HealthHealth BenefitHealth care facilityHealthcare SystemsHigh PrevalenceHuman immunodeficiency virus testIndividualInfectionInterdisciplinary StudyInterventionKenyaLeadLinkMalaiseMalariaMedicalMedical ResearchModelingNewly DiagnosedNotificationOutcomePartner NotificationPatientsPersonsPoliciesPreventionPrevention programPrevention strategyPreventive InterventionPrivatizationProviderPublic HealthRNAResearchResearch InstituteResearch Project GrantsResourcesRiskRisk BehaviorsRisk ReductionServicesSymptomsSyndromeTestingUniversitiesViral Load resultWashingtonWorkantiretroviral therapybasecare seekingcase findingclinical carecostcost effectivecost effectivenessdesigndisability-adjusted life yearseditorialefficacy testingexperiencehigh risk behaviorimprovedindexinginnovationinterdisciplinary approachnovelpoint of carepre-exposure prophylaxisprogramspublic health emergencyscreeningseropositiveservice interventionstandard of caretransmission processuptakevirologyyoung adult
项目摘要
Project Summary
Detection and management of acute HIV infection (AHI) is a clinical and public health emergency, and HIV
infections diagnosed among young adults are usually recent. Young adults with recent HIV acquisition
frequently seek care for symptoms, and could potentially be diagnosed through the health care system.
Although over 50% of persons living with HIV infection in Kenya are unaware of their status, facility-based HIV
testing is underutilized and available tests cannot diagnose AHI. Early recognition of HIV infection provides
considerable individual and public health benefits, including reduction in risk behavior, notification of partners in
need of HIV testing, access to counseling and treatment, and viral load suppression, if achieved. In this R01
application, we propose a multidisciplinary research project that builds on pilot work carried out in coastal
Kenya to detect AHI among young adults seeking care for symptoms compatible with acute retroviral
syndrome. Our highly productive research team, including collaborators from the University of Washington,
University of Oxford, and Kenya Medical Research Institute, has expertise in the fields of clinical care (Dr.
Graham), HIV prevention (Dr. Sanders), partner counseling and notification services (Dr. Farquhar), risk
behavior and network evaluations (Dr. Goodreau), and costing of interventions (Dr. Babigumira). Our specific
aims are to: (1) identify and test 1,500 adults identified by our AHI screening algorithm for acute and prevalent
(i.e., seropositive) HIV, linking all newly diagnosed HIV-infected patients to care and offering immediate
treatment; (2) offer assisted partner notification services (aPS) to all cases detected, screening partners for
acute and prevalent HIV infection and identifying local sexual networks; and (3) model the potential impact of
these two interventions on the Kenyan HIV epidemic, estimating incremental costs per HIV infection averted,
death averted, and disability-adjusted life-year averted using data on outcomes from our innovative program.
We will use a modified stepped wedge design to evaluate the yield of this screening intervention at 2 public
and 4 private health facilities in coastal Kenya, before and after intervention delivery. Our innovative
intervention will use standard HIV rapid tests to diagnose prevalent HIV infection and point-of-care HIV-1 RNA
testing to diagnose AHI among young adults presenting for care; use aPS to identify linked acute and prevalent
infections; and follow all newly diagnosed patients and their partners for 12 months to ascertain clinical
outcomes including linkage to care, ART initiation and virologic suppression in HIV-infected patients, and PrEP
uptake in uninfected individuals in discordant partnerships. Building on our pilot work on AHI screening
(Clinicaltrials.gov, NCT01876199) and our ground-breaking work on aPS in Kenya (Clinicaltrials.gov,
NCT01616420), as well as our expertise in modeling and cost-effectiveness analysis, we will provide
foundational data on the potential of this novel, combination HIV prevention intervention to significantly reduce
ongoing HIV transmission in Kenya and other high-prevalence African settings.
项目概要
急性艾滋病毒感染 (AHI) 的检测和管理是临床和公共卫生紧急事件,艾滋病毒
年轻人中诊断出的感染通常是最近发生的。最近感染艾滋病毒的年轻人
经常就症状寻求护理,并有可能通过医疗保健系统进行诊断。
尽管肯尼亚超过 50% 的艾滋病毒感染者不知道自己的状况,但基于设施的艾滋病毒感染者
检测未得到充分利用,可用的检测无法诊断 AHI。及早识别 HIV 感染可提供
相当大的个人和公共健康益处,包括减少危险行为、通知合作伙伴
如果实现的话,需要进行艾滋病毒检测、获得咨询和治疗以及抑制病毒载量。在这个R01
应用程序中,我们提出了一个多学科研究项目,该项目以沿海地区开展的试点工作为基础
肯尼亚将在寻求与急性逆转录病毒相关症状的年轻人中检测 AHI
综合症。我们高效的研究团队,包括来自华盛顿大学的合作者,
牛津大学和肯尼亚医学研究所在临床护理领域拥有专业知识(Dr.
格雷厄姆)、艾滋病毒预防(桑德斯博士)、伴侣咨询和通知服务(法夸尔博士)、风险
行为和网络评估(Goodreau 博士),以及干预措施的成本计算(Babigumira 博士)。我们的具体
目标是:(1) 通过我们的 AHI 筛查算法识别并测试 1,500 名成年人的急性和流行病
(即血清反应呈阳性)艾滋病毒,将所有新诊断的艾滋病毒感染者与护理联系起来,并立即提供治疗
治疗; (2) 为所有发现的病例提供辅助合作伙伴通知服务 (aPS),筛选合作伙伴
急性和流行的艾滋病毒感染并确定当地的性网络; (3) 对潜在影响进行建模
这两项针对肯尼亚艾滋病毒流行的干预措施,估计了每次避免艾滋病毒感染所增加的成本,
使用我们创新计划的结果数据避免了死亡,并避免了残疾调整生命年。
我们将使用改进的阶梯式楔形设计来评估 2 个公共场所的筛查干预效果
肯尼亚沿海的 4 个私人医疗机构在干预实施前后的情况。我们的创新
干预措施将使用标准 HIV 快速检测来诊断流行的 HIV 感染和护理点 HIV-1 RNA
对就诊的年轻人进行 AHI 诊断测试;使用 aPS 来识别相关的急性和流行病
感染;并对所有新诊断的患者及其伴侣进行为期 12 个月的随访,以确定临床情况
结果包括与护理的联系、HIV 感染者的 ART 启动和病毒学抑制以及 PrEP
在不和谐的伙伴关系中未感染者的吸收。以我们的 AHI 筛查试点工作为基础
(ClinicalTrials.gov,NCT01876199)以及我们在肯尼亚的 aPS 方面的开创性工作(ClinicalTrials.gov,
NCT01616420),以及我们在建模和成本效益分析方面的专业知识,我们将提供
关于这种新颖的艾滋病毒综合预防干预措施显着减少艾滋病毒感染的潜力的基础数据
肯尼亚和其他非洲高流行地区持续存在艾滋病毒传播。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Susan Marie Graham其他文献
Susan Marie Graham的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Susan Marie Graham', 18)}}的其他基金
University of Washington Developmental AIDS Research Center for Mental Health (UW ARCH)
华盛顿大学心理健康发展艾滋病研究中心 (UW ARCH)
- 批准号:
10569065 - 财政年份:2021
- 资助金额:
$ 57.26万 - 项目类别:
University of Washington Developmental AIDS Research Center for Mental Health (UW ARCH)
华盛顿大学心理健康发展艾滋病研究中心 (UW ARCH)
- 批准号:
10816852 - 财政年份:2021
- 资助金额:
$ 57.26万 - 项目类别:
Acceptability of Sustained-Release Antiretrovirals for Treatment in the US and sub-Saharan Africa
美国和撒哈拉以南非洲地区缓释抗逆转录病毒药物治疗的可接受性
- 批准号:
10020441 - 财政年份:2019
- 资助金额:
$ 57.26万 - 项目类别:
Acceptability of Sustained-Release Antiretrovirals for Treatment in the US and sub-Saharan Africa
美国和撒哈拉以南非洲地区缓释抗逆转录病毒药物治疗的可接受性
- 批准号:
10214487 - 财政年份:2019
- 资助金额:
$ 57.26万 - 项目类别:
Shikamana PrEP: A Community Participatory Approach to Integrating PrEP, Sexual Health, and Mental Health Services for GBMSM in Kenya
Shikamana PrEP:肯尼亚 GBMSM 整合 PrEP、性健康和心理健康服务的社区参与方法
- 批准号:
10064644 - 财政年份:2019
- 资助金额:
$ 57.26万 - 项目类别:
Acceptability of Sustained-Release Antiretrovirals for Treatment in the US and sub-Saharan Africa
美国和撒哈拉以南非洲地区缓释抗逆转录病毒药物治疗的可接受性
- 批准号:
10437700 - 财政年份:2019
- 资助金额:
$ 57.26万 - 项目类别:
Acceptability of Sustained-Release Antiretrovirals for Treatment in the US and sub-Saharan Africa
美国和撒哈拉以南非洲地区缓释抗逆转录病毒药物治疗的可接受性
- 批准号:
10678651 - 财政年份:2019
- 资助金额:
$ 57.26万 - 项目类别:
Impact of a novel screening program to detect acute and prevalent HIV infection and reduce HIV transmission
新型筛查计划对检测急性和流行的艾滋病毒感染并减少艾滋病毒传播的影响
- 批准号:
9202511 - 财政年份:2016
- 资助金额:
$ 57.26万 - 项目类别:
Endothelial Activation and Microangiopathy in HIV-related Cardiovascular Disease
HIV 相关心血管疾病中的内皮激活和微血管病
- 批准号:
8984228 - 财政年份:2015
- 资助金额:
$ 57.26万 - 项目类别:
相似国自然基金
剪接因子U2AF1突变在急性髓系白血病原发耐药中的机制研究
- 批准号:82370157
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
IKZF1-N159Y/S热点突变在急性白血病中的致病机制研究
- 批准号:82300168
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
NMNAT1上调B7-H3介导急性早幼粒细胞白血病免疫逃逸的作用和机制研究
- 批准号:82300169
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
支链氨基酸转氨酶1在核心结合因子急性髓细胞白血病中的异常激活与促进白血病发生的分子机制研究
- 批准号:82370178
- 批准年份:2023
- 资助金额:48 万元
- 项目类别:面上项目
SRSF3/LRP5/Wnt信号通路在急性淋巴细胞白血病中的作用及机制研究
- 批准号:82370128
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
相似海外基金
Screen Smart: Using Digital Health to Improve HIV Screening and Prevention for Adolescents in the Emergency Department
智能屏幕:利用数字健康改善急诊科青少年的艾滋病毒筛查和预防
- 批准号:
10711679 - 财政年份:2023
- 资助金额:
$ 57.26万 - 项目类别:
Integrating Trauma-Informed Research in Assessment of Young Women Engaged in HIV Cure Research (Post-Intervention Control) Trial with Analytical Treatment Interruption in Durban, South Africa
将创伤知情研究纳入南非德班参与艾滋病毒治疗研究(干预后控制)试验的年轻女性与分析治疗中断的评估中
- 批准号:
10761531 - 财政年份:2023
- 资助金额:
$ 57.26万 - 项目类别:
Harnessing big data to arrest the HIV/HCV/opioid syndemic in the rural and urban South
利用大数据遏制南方农村和城市的艾滋病毒/丙型肝炎/阿片类药物流行病
- 批准号:
10696612 - 财政年份:2023
- 资助金额:
$ 57.26万 - 项目类别:
BEATS: Binge drinking Ecological Antecedents with Transdermal alcohol monitoring Study.
BEATS:通过透皮酒精监测研究暴饮暴食的生态前因。
- 批准号:
10827305 - 财政年份:2023
- 资助金额:
$ 57.26万 - 项目类别:
Harnessing big data to arrest the HIV/HCV/opioid syndemic in the rural and urban South
利用大数据遏制南方农村和城市的艾滋病毒/丙型肝炎/阿片类药物流行病
- 批准号:
10696612 - 财政年份:2023
- 资助金额:
$ 57.26万 - 项目类别: